Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$26,541 Mln
P/E Ratio
20.07
P/B Ratio
4.37
Industry P/E
--
Debt to Equity
0.22
ROE
0.23 %
ROCE
9.9 %
Div. Yield
0 %
Book Value
33.08
EPS
7.49
CFO
$14,718.45 Mln
EBITDA
$19,632.32 Mln
Net Profit
$6,311.59 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
| -21.91 | -13.50 | -24.57 | -34.67 | -11.23 | 2.46 | 8.27 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Midcap 400
| -8.37 | -2.02 | -11.96 | -1.34 | 3.58 | 11.87 | 6.46 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
| -14.96 | 12.93 | -27.38 | 57.47 | 15.96 | 33.00 | 18.55 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 257.19 | 32,984.47 | -- | 362.29 | |
| 131.87 | 14,047.06 | -- | -8.58 | |
| 23.62 | 17,785.46 | -- | -94.9 | |
| 300.76 | 13,571.46 | 12.05 | 19.23 |
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments:... Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina. Address: 2400 Ellis Road, Durham, NC, United States, 27703 Read more
CEO & Chairman
Mr. Ari Bousbib
CEO & Chairman
Mr. Ari Bousbib
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of IQVIA Holdings Inc (IQV) stood at $ 26,899 Mln as on 31-Dec-24
The share price of IQVIA Holdings Inc (IQV) is $153.45 (NYSE) as of 29-Apr-2025 16:10 EDT. IQVIA Holdings Inc (IQV) has given a return of -11.23% in the last 3 years.
IQVIA Holdings Inc (IQV) has a market capitalisation of $ 26,541 Mln as on 29-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/E ratio of IQVIA Holdings Inc (IQV) is 20.07 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the IQVIA Holdings Inc (IQV) and enter the required number of quantities and click on buy to purchase the shares of IQVIA Holdings Inc (IQV).
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina. Address: 2400 Ellis Road, Durham, NC, United States, 27703
The CEO & director of Mr. Ari Bousbib. is IQVIA Holdings Inc (IQV), and CFO & Sr. VP is Mr. Ari Bousbib.
There is no promoter pledging in IQVIA Holdings Inc (IQV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3,132
|
|
|
2,451
|
|
|
1,405
|
|
|
1,318
|
| IQVIA Holdings Inc. (IQV) | Ratios |
|---|---|
|
Return on equity(%)
|
22.55
|
|
Operating margin(%)
|
15.18
|
|
Net Margin(%)
|
8.91
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of IQVIA Holdings Inc (IQV) was $1,373 Mln.
$3.32
(
